AbbVie Inc.
ABBV
$163.79
$2.981.85%
| 12/31/2023 | 09/30/2023 | 06/30/2023 | 03/31/2023 | 12/31/2022 | |
|---|---|---|---|---|---|
| Net Income | -58.91% | -51.41% | -31.27% | -39.22% | 2.55% |
| Total Depreciation and Amortization | 2.73% | 5.91% | 6.55% | 2.18% | -0.63% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 36.57% | 140.06% | 55.17% | 114.51% | 17.29% |
| Change in Net Operating Assets | 3,092.55% | 258.89% | 214.16% | 121.69% | 92.89% |
| Cash from Operations | -8.44% | 12.94% | 11.43% | 6.23% | 9.51% |
| Capital Expenditure | -11.80% | -17.34% | -4.80% | 6.96% | 11.69% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -54.03% | 37.78% | 53.20% | 49.07% | 58.25% |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -101.04% | -89.21% | 394.83% | 326.83% | 151.01% |
| Cash from Investing | -222.47% | -25.53% | 99.94% | 113.05% | 73.42% |
| Total Debt Issued | -- | -100.00% | -100.00% | -100.00% | 100.00% |
| Total Debt Repaid | 71.25% | 18.78% | -9.89% | 23.70% | -53.31% |
| Issuance of Common Stock | -31.30% | -28.87% | -40.60% | -33.89% | 7.38% |
| Repurchase of Common Stock | -32.62% | -22.24% | -22.09% | -21.95% | -59.21% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -4.94% | -5.77% | -6.56% | -7.53% | -8.44% |
| Other Financing Activities | 32.67% | -1.92% | -54.89% | -52.95% | -63.50% |
| Cash from Financing | 30.56% | -4.18% | -28.69% | -5.19% | -30.27% |
| Foreign Exchange rate Adjustments | 108.06% | 104.42% | 60.00% | -74.29% | 36.08% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 762.94% | 515.71% | 1,052.00% | 116.76% | -142.02% |
